Sales of Tecentriq sales rose 64% to around $2.2 billion in the first nine months of this year, but Avastin has started to succumb to biosimilar competition, shrinking 22% to a little over $4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback